{"schema":"hottub-news/story/v1","story":"st_e2wkr24mzczskusxau5q","title":"First-line trastuzumab deruxtecan (T-DXd) in metastatic HER2-mutant NSCLC: DESTINY-Lung04 primary results","title_en":null,"outlets":1,"brief":null,"page":"https://hottub.news/stories/first-line-trastuzumab-deruxtecan-t-dxd-in-metastatic-her2-mutant-nsclc-e2wkr24mzc","count":1,"items":[{"id":"n_e2wkr24mzczskusxau5q","seq":801726,"kind":"article","title":"First-line trastuzumab deruxtecan (T-DXd) in metastatic HER2-mutant NSCLC: DESTINY-Lung04 primary results","url":"https://www.onclive.com/view/first-line-trastuzumab-deruxtecan-t-dxd-in-metastatic-her2-mutant-nsclc-destiny-lung04-primary-results","published":"2026-09-30T01:45:00Z","seen":"2026-09-30T01:46:20Z","lang":"en","source":{"id":"onclive.com","name":"onclive.com","domain":"onclive.com","outlet":{"wikidata":"Q140944690","name":"OncLive","type":"website","designations":["publication","website"]}},"via":"gdelt-gkg-english","topics":["health","economy"],"entities":[{"id":"Q80109553","name":"trastuzumab deruxtecan","type":"other"}],"story":"st_e2wkr24mzczskusxau5q","category":"health","category_p":0.30000001192092896,"category2":"science-technology","sentiment":"neutral","tone":-0.20000000298023224,"political":0.07999999821186066}]}